This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. Publication of this PTJA10 was postponed by 5 weeks due to the unavailability of the EPAR. This Joint Assessment aims to compare the clinical effectiveness and safety of crizanlizumab in the target patient populations with relevant comparators according to the national requirements of EUnetHTA partners.
Below is the documentation provided by the Joint Assessment Authoring Team (Project Plan, Assessment Report and responses to the Factual Accuracy Check performed by Novartis); and the Core Submission Dossier prepared by Novartis, the Marketing Authorisation Holder of crizanlizumab.
For any questions regarding the assessment, please contact WP4_Pharmaceuticals@zinl.nl
PTJA10 – Final Project Plan
PTJA10 – Final Assessment Report
PTJA10 – MAH Core Submission Dossier
PTJA10 – Plain Language Summary
PTJA10 – External Comments – Factual accuracy Check MAH
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.